AMPH: Cooler Outlook And AMP-004 Uncertainty Will Shape Balanced Future Prospects

Amphastar Pharmaceuticals' analyst price target has been revised from $25.45 to $19.00 as analysts factor in updated Q1 models, a higher discount rate, more uncertain 2026 revenue expectations, and questions around AMP-004 interchangeability status.

Analyst Commentary

Recent research coverage on Amphastar Pharmaceuticals points to a cooler tone, with several bearish analysts trimming price targets and tempering expectations around the company’s medium term outlook. The common threads are uncertainty around the 2026 revenue profile, questions about AMP-004 interchangeability, and what those factors could mean for valuation and execution risk.

Bearish Takeaways

Bearish analysts have cut Amphastar Pharmaceuticals' price targets into the high teens to around US$20, reflecting updated Q1 models and more cautious 2026 assumptions.
There is expressed concern that revenue in 2026 and 2027 is hard to predict, which raises questions for investors who are trying to gauge Amphastar’s longer term growth path.
Some bearish analysts say they have less confidence that Amphastar can meet its 2026 outlook, signaling execution risk compared with previously discussed expectations.
Uncertainty around AMP-004 securing interchangeability status is flagged as a risk, since a less favorable outcome could affect Amphastar’s growth potential and support for current valuation levels.

What’s in the News for Amphastar Pharmaceuticals

Amphastar Pharmaceuticals received FDA approval for Rextovy, an over the counter 4 milligram naloxone hydrochloride nasal spray for emergency treatment of opioid overdose, allowing consumers to buy it without a prescription in pharmacies, convenience stores, and online. (Source: FDA approval announcement)
Rextovy contains the same active ingredient as other naloxone nasal sprays and is described as an additional life saving medication that can rapidly reverse the effects of an opioid overdose, which is the standard treatment approach for such events. (Source: FDA approval announcement)
The FDA highlighted that multiple approved nonprescription naloxone formulations, including Rextovy from Amphastar Pharmaceuticals, may expand access, increase market availability, encourage competition that could reduce cost, and offer alternative sourcing options. (Source: FDA approval announcement)
Product packaging for Rextovy includes pictorial directions with five clear steps, including calling 911 after administering the first dose, and is described as safe to use even when it is uncertain whether opioids are present in a person’s system. (Source: FDA approval announcement)

Valuation Changes for Amphastar Pharmaceuticals

Fair Value: revised from $25.45 to $19.00, a lower central estimate for Amphastar Pharmaceuticals' equity value per share.
Discount Rate: moved slightly higher from 6.98% to about 7.15%, which implies a modestly higher required return for the stock in updated models.
Revenue Growth: updated from 2.19% to about 2.93%, which indicates analysts are now using a higher top line growth assumption in their Amphastar Pharmaceuticals forecasts.
Net Profit Margin: adjusted from 14.25% to about 10.02%, which reflects a lower profitability assumption in future periods.
Future P/E: shifted from 11.39x to about 10.98x, which points to a slightly lower earnings multiple being applied in the current valuation work.

0 views

Key Takeaways

Heavy dependence on a few key products increases vulnerability to competitive threats and shifting market trends, risking overall revenue and earnings stability.
Greater costs, market saturation, and regulatory headwinds will challenge profitability, while new competition in biosimilars and generics threatens long-term growth.
Strategic expansion of domestic manufacturing, investment in proprietary products, and focus on complex generics position Amphastar for higher margins, market share gains, and resilient earnings.

Catalysts

About Amphastar Pharmaceuticals

A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.What are the underlying business or industry changes driving this perspective?

Intensifying pricing pressure and increased competition in key legacy products such as glucagon and epinephrine are expected to lead to further erosion of both unit volumes and average selling prices, resulting in declining revenues and compressed gross margins over the long term.
Heavy revenue reliance on a small number of products, particularly BAQSIMI and Primatene Mist, exposes Amphastar to significant risk if competitors, new entrants, or shifting market preferences undermine these product lines, threatening overall revenue and earnings stability.
The company faces rising operating costs due to higher expenses in research and development, clinical trials, and compliance, yet the increasingly saturated and genericized injectables market will likely prevent meaningful price increases, leading to shrinking net margins and weaker profitability.
The approval environment for complex generics and biosimilars is becoming more competitive, and the expected influx of biosimilars and biologics may gradually erode the addressable market for traditional generic injectables, undermining Amphastar's future growth prospects and revenue streams.
Escalating regulatory scrutiny, industry consolidation among distributors and PBMs, and competition from low-cost overseas manufacturers are set to intensify, putting persistent downward pressure on revenue, gross margin, and earnings for Amphastar in future years.

Amphastar Pharmaceuticals Earnings and Revenue Growth

Amphastar Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Amphastar Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Amphastar Pharmaceuticals's revenue will grow by 2.9% annually over the next 3 years.
The bearish analysts assume that profit margins will shrink from 11.0% today to 10.0% in 3 years time.
The bearish analysts expect earnings to reach $78.8 million (and earnings per share of $1.59) by about June 2029, down from $79.2 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 11.2x on those 2029 earnings, up from 10.9x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 15.1x.
The bearish analysts expect the number of shares outstanding to decline by 5.17% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.15%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Amphastar's significant expansion of its California headquarters to quadruple domestic manufacturing capacity enhances supply chain resilience and positions the company to benefit from ongoing geopolitical trends favoring U.S.-based production, which may help protect and improve gross margins and profitability.
Continued investment in R&D and a pipeline of proprietary and complex injectable products, including potential FDA approvals for AMP-002 and AMP-015, create new high-margin revenue streams that may offset generic price erosion and support long-term earnings growth.
Strong growth in BAQSIMI sales, driven by successful global commercialization and favorable pricing trends, signals Amphastar's ability to effectively integrate and grow newly acquired products, with the potential for sustained revenue and net income increases.
Amphastar's vertical integration in manufacturing and focus on complex and hard-to-replicate generics provide defensive advantages amid rising competition, allowing the company to manage costs effectively and support steady or improving net margins.
Strategic emphasis on branded, proprietary, and biosimilar products alongside a robust U.S.-based infrastructure aligns with long-term industry trends such as expanding demand for specialty pharmaceuticals, which may help the company capture greater market share and drive revenue and earnings growth over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Amphastar Pharmaceuticals is $19.0, which represents up to two standard deviations below the consensus price target of $22.83. This valuation is based on what can be assumed as the expectations of Amphastar Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $19.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $785.8 million, earnings will come to $78.8 million, and it would be trading on a PE ratio of 11.2x, assuming you use a discount rate of 7.2%.
Given the current share price of $19.53, the analyst price target of $19.0 is 2.8% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Amphastar Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Intensifying Pricing Pressure Will Erode Margins And Revenue